Chrystal Capital Partners LLP
Bildnachweis: © ala Stock.Adobe.com.
Chrystal Capital Partners LLP are close to reaching a first close on Verdite Capital Fund I LP, a Guernsey regulated investment fund that will create a diversified portfolio of high-quality investments in the legal global medical cannabis sector. Having deployed over $210m on behalf of investors into the cannabinoid sector, Chrystal Capital, as sole investment advisor to Verdite, has assembled a highly experienced team and Advisory Board to help clients gain exposure to this emerging global sector. With $85m already committed the fund is targeting a first close of $100m later in the year.
|Capital under management||First Close target $100, Second Close $200m|
|Investment requirements and financing offer||We have secured the backing of a cornerstone investor of $75m
and the support of several high net worth individuals and family
offices. We are seeking additional investors to join us to provide
growth capital to this high growth and under financed sector.
|Industry focus||The fund will focus on investments in the global legal cannabis sector, with a particular interest in businesses operating in the Wellness, Pharmaceutical and Medical sub-sectors. We will allocate our capital mainly in Europe and North America into a diversified portfolio of 10-15 investments across the industry value chain.|
|Portfolio and exits
||The fund currently has no portfolio, but Chrystal Capital has
invested over $210m into the sector on behalf of investors. The current portfolio has an unrealised value of 5.2x investment while successful exits have achieved returns of 2.1x.
|Memberships in networks/associations||Member of the British Venture Capital Association, fully regulated by the Financial Conduct Authority with the fund approved and regulated by the Guernsey Financial Services Commission.|
|Date of Incorporation/
Number of Employees
|Address||24 Grosvenor Street
London, W1K 4QN
|Telephone||+44 20 7850 4760|
|Social Media||LinkedIn: chrystal-capital-partners-llp|